Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
OXB-302 is a gene-based cancer immunotherapy targeting a wide range of tumours and a number of haematological malignancies.
OXB-302 is a novel oncology product that combines Oxford Biomedica’s lentiviral vector platform and 5T4 technology platforms. This cell therapy uses the LentiVector® platform to engineer patients’ harvested T-cells to express an antibody against the 5T4 antigen, which is expressed on the cell surface in many common cancers. These T-cells are then infused back into the patient, and subsequently recognise the 5T4 tumour antigen and initiate cell killing immune mechanisms.
Proof of concept
OXB-302 has completed pre-clinical development, delivering encouraging efficacy in an industry standard in vivo tumour challenge model.
Following the successful completion of preclinical development, planning for a Phase I/II clinical study is well underway, with a regulatory submission anticipated in the near future.
The targeted cancer treatment and immunotherapy market is forecast to grow to $36.8 billion by 2019. With a large number of cancers expressing the 5T4 antigen, OXB-302 has significant market potential if successful in any of its target indications.